Edwards Lifesciences (NYSE:EW) VP Daniel Lippis Sells 1,019 Shares

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of the company’s stock in a transaction dated Wednesday, March 11th. The stock was sold at an average price of $85.38, for a total transaction of $87,002.22. Following the completion of the transaction, the vice president owned 33,934 shares in the company, valued at approximately $2,897,284.92. The trade was a 2.92% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Edwards Lifesciences Stock Down 0.5%

NYSE EW traded down $0.45 during mid-day trading on Thursday, reaching $84.64. The stock had a trading volume of 444,603 shares, compared to its average volume of 4,542,033. The company has a fifty day moving average price of $82.49 and a 200 day moving average price of $81.55. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.72 and a quick ratio of 3.09. Edwards Lifesciences Corporation has a 1 year low of $65.94 and a 1 year high of $87.89. The stock has a market cap of $49.16 billion, a PE ratio of 46.22, a price-to-earnings-growth ratio of 2.24 and a beta of 0.93.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The business had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.Edwards Lifesciences’s quarterly revenue was up 13.3% compared to the same quarter last year. During the same period last year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Corient Private Wealth LLC raised its holdings in Edwards Lifesciences by 20.7% in the fourth quarter. Corient Private Wealth LLC now owns 100,051 shares of the medical research company’s stock worth $8,547,000 after purchasing an additional 17,144 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Edwards Lifesciences by 0.7% in the 4th quarter. Hsbc Holdings PLC now owns 2,148,974 shares of the medical research company’s stock worth $183,188,000 after buying an additional 15,577 shares during the last quarter. Pure Financial Advisors LLC bought a new position in shares of Edwards Lifesciences during the 4th quarter worth approximately $217,000. Rehmann Capital Advisory Group lifted its position in Edwards Lifesciences by 2.1% during the fourth quarter. Rehmann Capital Advisory Group now owns 6,399 shares of the medical research company’s stock valued at $546,000 after acquiring an additional 130 shares during the last quarter. Finally, Tulsa Wealth Advisors INC acquired a new stake in Edwards Lifesciences in the fourth quarter valued at approximately $804,000. 79.46% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the company. Evercore reaffirmed an “outperform” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a report on Monday, January 5th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Citigroup reaffirmed a “buy” rating and set a $101.00 target price (up from $96.00) on shares of Edwards Lifesciences in a research note on Thursday, December 11th. Robert W. Baird set a $90.00 price objective on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $95.00 price objective (down from $108.00) on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Three investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.